---
title: "OneSource Specialty Pharma Ltd (ONESOURCE) — Share Price, Financials & Analysis"
symbol: "ONESOURCE"
company: "OneSource Specialty Pharma Ltd"
canonical: "https://tapetide.com/stocks/ONESOURCE"
isin: "INE013P01021"
nse_symbol: "ONESOURCE"
bse_code: "544292"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 17827.42
generated_at: "2026-09-13T19:57:02.877Z"
---

# OneSource Specialty Pharma Ltd (ONESOURCE)

Canonical page: https://tapetide.com/stocks/ONESOURCE

## Company

- **NSE Symbol:** ONESOURCE
- **BSE Code:** 544292
- **ISIN:** INE013P01021
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-01-24
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** onesourcecdmo.com

## About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO 
services across all phases of pre-clinical 
and clinical development and commercial 
supply of biologics[1]

## Latest Price

- **Price:** ₹1592.2
- **Change:** +50.3 (+3.26%)
- **Open:** ₹1548.1
- **Day High:** ₹1624.7
- **Day Low:** ₹1530
- **Previous Close:** ₹1541.9
- **Volume:** 919086
- **As Of:** 2026-09-11T10:29:48+00:00

## Key Fundamentals

Observed at 2026-09-11T04:35:02.335685Z.

- **Market Cap:** ₹17827.42 Cr
- **Classification:** Smallcap
- **P/E (reported):** -364.5
- **EPS (TTM):** ₹-4.24
- **Book Value:** ₹508.58
- **Price to Book:** 3.04
- **Dividend Yield:** 0%
- **ROE:** -0.29%
- **ROCE:** 1.54%
- **Debt to Equity:** 0.26
- **Revenue (yearly):** ₹1421.59 Cr
- **Net Income:** ₹-94.17 Cr
- **EBITDA:** ₹294.29 Cr
- **52-Week High:** ₹1925
- **52-Week Low:** ₹1057
- **RSI (14):** 47.47

## Tapetide Score

- **Score:** 35 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 6 (of 4473 scored stocks)
- **Confidence:** 93%
- **Data coverage:** 86%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 22.35 | 9% |
| growth | 22.02 | 9% |
| momentum | 32.45 | 12% |
| ownership | 82.6 | 24% |
| quality | 17.34 | 22% |
| valuation | 23.59 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 3.13 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.39% over last 3 years.
- Promoters have pledged 37.2% of their holding.
- Company has high debtors of 177 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 36.71% | 58.34% | 42.29% |
| ebitda margin growth | 30.5% | -38.1% | -142.96% | -129.98% |
| net income growth | 443.48% | 444.34% | 24% | 8% |
| revenue growth | 5.2% | -2.78% | 232% | 131% |
| roce | 129.97% | -103.78% | -104.78% | -18.19% |
| roe | 443.48% | -99.69% | -48.54% | -98.14% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | -114 | -19 | -3.8 | 22 | 23 | 36 | 43 | 27 | 28 | 6 | 21 | 27 |
| Other Income | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | 0 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| Profit before tax | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | 0 | 20 |
| Tax % | 0 | 0 | 0 | -88 | 12 | 4 | -19 | -96 | -83 | -5 | -1630 | -23 |
| Net Profit | -114 | -130 | -40 | -6 | -42 | -69 | 98 | 0 | 10 | -89 | 5 | 25 |
| EPS in Rs | — | — | — | — | — | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.4 | 2.18 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 21 | 132 | 39 | 172 | 1445 | 1422 | 1543 |
| Expenses | 93 | 229 | 199 | 254 | 978 | 1117 | 1204 |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 | 339 |
| OPM % | -334 | -73 | -415 | -48 | 32 | 21 | 22 |
| Other Income | 1 | 4 | -526 | -143 | -94 | 5 | 2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 283 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 | -67 |
| Tax % | 0 | 0 | 0 | 0 | -73 | -20 | — |
| Net Profit | -121 | -231 | -800 | -391 | -18 | -74 | -49 |
| EPS in Rs | — | — | — | — | -1.57 | -6.44 | -4.24 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1009 | 781 | 392 | 5869 | 5820 |
| Borrowings | 386 | 1154 | 864 | 562 | 772 | 1504 |
| Other Liabilities | 96 | 276 | 365 | 468 | 1005 | 875 |
| Total Liabilities | 1258 | 2442 | 2015 | 1426 | 7657 | 8210 |
| Fixed Assets | 633 | 1231 | 1361 | 863 | 6118 | 6233 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 314 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other Assets | 195 | 722 | 314 | 356 | 1305 | 1648 |
| Total Assets | 1258 | 2442 | 2015 | 1426 | 7657 | 8210 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -118 | -416 | -163 | -107 | -68 | 9 |
| Cash from Investing Activity | -207 | -692 | -68 | 511 | -201 | -495 |
| Cash from Financing Activity | 381 | 1162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164 | 430 | 108 | 130 | -13 | 6 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1805 | 615 | 258 | 222 | 360 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 1461 | 232 | 212 | 180 | 230 |
| Working Capital Days | -2392 | -1291 | -6745 | -877 | -58 | -29 |
| ROCE % | — | -10 | -12 | -12 | 6 | 1 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 37.77% | 34.25% | 29.79% | 29.77% | 29.93% | 30.48% | 30.48% |
| FIIs | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.5% | 19.19% |
| DIIs | 12.56% | 18.04% | 18.1% | 18.49% | 18.81% | 20.61% | 23.38% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 13.05% | 12.5% | 13.25% | 12.42% | 12.39% | 12.18% | 11.29% |
| Others | 19.18% | 16.67% | 20.17% | 19.93% | 19.63% | 19.23% | 15.65% |
| No. of Shareholders | 98425 | 82712 | 87760 | 87416 | 84595 | 79460 | 77899 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 6 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1550.09 | Buy |
| EMA (10) | 1553.05 | Buy |
| SMA (20) | 1538.63 | Buy |
| EMA (20) | 1553.3 | Buy |
| SMA (50) | 1592.3 | Sell |
| EMA (50) | 1581.89 | Buy |
| SMA (100) | 1665.26 | Sell |
| EMA (100) | 1601.28 | Sell |
| SMA (200) | 1580.03 | Buy |
| EMA (200) | 1616.29 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 55.05 | Neutral |
| MACD (12,26,9) | -6.86 | Buy |
| Stochastic (14,3,3) | 45.76 | Neutral |
| ADX (14) | 14.69 | Neutral |
| Williams %R (14) | -31.9 | Neutral |
| ATR (14) | 58.5 | High Volatility |
| ROC (12) | 7.32 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 39.35 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 1 | 25% |

Based on 4 analyst ratings, observed at 2026-09-11T04:35:05.431218+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Allotment of 21,450 equity shares of Re. 1 each/- under ONESOURCE ESOP 2021 on April 09, 2026 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 9 Apr - Allotment of 21,450 equity shares of Re. 1 each/- under ONESOURCE ESOP 2021 on April 09, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5556d0af-2f64-460b-b663-4e71ffcc295c.pdf) |
| 7 May - Regarding earnings call to be held on May 13, 2026 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 May - Regarding earnings call to be held on May 13, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/26c1bc13-9e14-4ec3-b8f1-b5f1c7740d4b.pdf) |
| 7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1. | [Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015 7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4eeaf715-dd02-451c-a227-3310779c919e.pdf) |
| 6 Mar - Board reviewing merger to acquire Steriscience Poland and Baroda; in-principle approval; review within six months (Mar 6, 2026) | [Update On Composite Scheme Of Arrangement 6 Mar - Board reviewing merger to acquire Steriscience Poland and Baroda; in-principle approval; review within six months (Mar 6, 2026)](https://www.bseindia.com/xml-data/corpfiling/AttachHis/de1f0a5d-c375-413a-9d97-2337cc3bdbb9.pdf) |
| 5m - Press release: Orbicular''s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic (Semaglutide Injection), supported by OneSource as CDMO Partner. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5m - Press release: Orbicular''s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic (Semaglutide Injection), supported by OneSource as CDMO Partner.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/407eac56-c7f1-463c-8d61-58044f912231.pdf) |
| 5 Mar - CARE withdrew company's bank facilities and NCD ratings (requested); India Ratings IND A-; Positive reaffirmed Dec 2025. | [Announcement under Regulation 30 (LODR)-Credit Rating 5 Mar - CARE withdrew company's bank facilities and NCD ratings (requested); India Ratings IND A-; Positive reaffirmed Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1a2e96a2-5382-411b-969f-ba8b6d7b6dbd.pdf) |
| 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/60f74551-1b52-4ae7-afeb-7a7edf45cf9e.pdf) |
| 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/60f74551-1b52-4ae7-afeb-7a7edf45cf9e.pdf) |
| 4 Mar - Schedule of Analyst/Investor''s meet-Intimation under Regulation 30 of the SEBI Listing Regulations. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Mar - Schedule of Analyst/Investor''s meet-Intimation under Regulation 30 of the SEBI Listing Regulations.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/29c41b61-a574-4f15-a6c6-6277479b5289.pdf) |
| 29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/04868d49-5eea-4d15-82d0-13b75e5295da.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2aa2811f-43a0-48cd-812c-ccf51c2d49b5.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22ff8df9-88f1-40b4-a835-c09fcad3f938.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af0b21d2-f257-43d9-bbda-76f2702f1d4e.pdf) |
| 2026-08-31 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf35b4e-3c04-474d-a8f5-62d5852ae594.pdf) |
| 2026-08-31 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5791fc38-5d57-4709-bc0a-92a61486428c.pdf) |
| 2026-08-31 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=add95a5c-d31c-4d72-8e40-e653f7c99b75.pdf) |
| 2026-08-31 | [Notice Of The 19Th AGM Dated September 23 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a7e802f-40b7-4a26-8d8d-be63f9c39b3c.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=763d5778-5847-4fc4-a8a1-9465dc2b1001.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Credit Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b107e84-77fe-41d8-99ec-ac4b1771c3c0.pdf) |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e848e3b-05cc-4344-8ab6-12fdae5ab56f.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68ac2e6d-2525-4659-9e84-98669cd0403f.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d5854cf-1073-4e17-9207-4cd759d11191.pdf) |
| 2025-11-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5058b94e-ec42-4d8f-aef1-d5dea9775add.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48bc2dff-06ad-4fe0-ab4e-f965913c4674.pdf) |
| 2025-05-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cbbcae2-b576-46b6-8acb-4c43e18b557a.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19be8faf-7d1c-4b1b-8df0-afc8c0bb64f4.pdf) |
| 2026-05-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30473bff-5e49-4d8d-8315-aa88e013f384.pdf) |
| 2026-01-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2ed4954-f9f4-4e9a-88db-abf5f5743f40.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70ed8ddf-b81e-4766-b263-da1dcba39ec2.pdf) |
| 2025-08-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90b73cfb-4867-4727-8bcc-bb5e0e78fe50.pdf) |
| 2025-05-06 | [Intimation Of Investor Meet Held On May 06 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=35c7296b-09c7-42e3-b3b3-89de247c04c4.pdf) |
| 2025-01-30 | [Intimation Of The Link Of The Audio Recording Of The Investor Call Held On 29Th January 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62e5d771-ea16-42f1-a0e9-10f7df9e78e3.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33806495-00c9-46a9-94af-ba64887fbac6.pdf) |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33806495-00c9-46a9-94af-ba64887fbac6.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5058b94e-ec42-4d8f-aef1-d5dea9775add.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d5854cf-1073-4e17-9207-4cd759d11191.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4d5854cf-1073-4e17-9207-4cd759d11191.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bd5dff00-7ff3-4fb3-a1ac-66f1860c8dfa.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/bd5dff00-7ff3-4fb3-a1ac-66f1860c8dfa.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3cbbcae2-b576-46b6-8acb-4c43e18b557a.pdf) |
| Jan 2026 | [Concall - Jan 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f9a54424-cf34-41e2-8590-eba15ca29830.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dcc3519b-1b02-474a-854f-df4a19c75521.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-05-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd5dff00-7ff3-4fb3-a1ac-66f1860c8dfa.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2025-11-11 | [Financial Results For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db6745d9-c20a-4764-ac80-0f621cec4646.pdf) |
| 2025-01-29 | [Results-Financial Results For The Quarter Ended December 31. 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd527444-b149-4fea-bb61-eb53d68beeaa.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc7ae255-5594-44e0-acf6-1b6c228a3a31.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:57:02.877Z.